



FINANCIAL STATEMENTS

For the year ended 31st December 2021

**International Centre for Diarrhoeal
Disease Research, Bangladesh (icddr,b)**

**Independent Auditor's Report
and Audited Financial Statements**

For the year ended 31st December 2021

Index to the independent auditor's report and audited financial statements

	Page
Corporate information.....	1
Independent auditor's report.....	2
Statement of financial position.....	6
Statement of activities.....	7
Statement of changes in funds.....	8
Statement of cash flows.....	9
Notes to the financial statements.....	10
Note 1: Reporting entity.....	10
Note 2: Basis of preparation.....	10
Note 3: Significant accounting policies.....	11
Note 4: Property, plant and equipment.....	17
Note 5: Capital work in progress.....	18
Note 6: Investments.....	18
Note 7: Inventories.....	19
Note 8: Accounts receivable.....	19
Note 9: Loans and advances.....	20
Note 10: Cash and cash equivalents.....	20
Note 11: Deferred contributions.....	20
Note 12: Accounts and other payables.....	21
Note 13: Provisions.....	21
Note 14: Hospital endowment fund.....	22
Note 15: Centre endowment fund.....	22
Note 16: Collateral fund.....	22
Note 17: Operating fund.....	22
Note 18: CWIP reserve fund.....	22
Note 19: Revaluation reserve on land.....	23
Note 20: Special reserve fund.....	23
Note 21: Capital investment reserve fund.....	23
Note 22: Donor grants.....	23
Note 23: Other receipts.....	28
Note 24: Mandatory committee meeting expenses.....	28
Note 25: Other expenditure.....	28
Note 26: Operating leases.....	28
Note 27: Breakdown of total expenditure.....	29
Note 28: Financial risks.....	29
Note 29: Related parties.....	30
Note 30: Contingent liability.....	30
Note 31: Post COVID-19 impact on icddr,b.....	30

CORPORATE INFORMATION

Board of Trustees

Mrs. Nancy Y Cheng, Canada

Chair, Board of Trustees

Dr. John D Clemens, USA (up to March 2021)

Executive Director, icddr,b

Dr. Tahmeed Ahmed, Bangladesh (from Feb 2021)

Executive Director, icddr,b

Dr. Abbas Bhuiya

GoB representative & Deputy Chair,
Fund Development Committee and Member, Programme Committee

Mr. Md. Lokman Hossain Miah (from April 2021)

GoB representative, Member, Finance and Audit Committee

Ms. Fatima Yasmin

GoB representative & Chair, Fund Development Committee

Mr. Md. Abdul Mannan (up to April 2021)

GoB representative

Mr. Amol Khisty, India

Chair, Finance and Audit Committee

Dr. Ogutu Bernhards Ragama, Kenya

Acting Deputy Chair (June to Oct 2021), Deputy Chair,
Finance and Audit Committee (from October 2021)

Dr. Sara Bennett, UK

Member, Finance and Audit Committee & HR Committee

Prof Abdullah H Baqui, USA

Chair, Programme Committee

Dr. Thein Thein Htay, Myanmar

Member, Programme Committee; Acting Chair, HR Committee
(up to Sep 2021), Member HR Committee (from Oct 2021)

Dr. Therese Dooley, Ireland (up to July 2021)

UNICEF representative & Member, HR Committee

Dr. Peter Harvey, UK (from Oct 2021)

UNICEF representative & Member, HR Committee and Finance and
Audit Committee

Dr. Anu Kantele, Finland

Deputy Chair, Programme Committee

Dr. S Siswanto, Indonesia

WHO representative, Member, Fund Development, Program
Committee, HR Committee

Dr. Fred Binka, Ghana

Member (Up to Sep 2021) & Chair, HR Committee (from Oct 2021)
and Member, Program Committee

Dr. Andrea Lucard, Switzerland

Member, Fund Development Committee

Address:

icddr,b
68, Shaheed Tajuddin Ahmed Sarani,
Mohakhali, Dhaka -1212,
Bangladesh.

Tel: +880 (0)2-2222-77001 to 10

Fax: (+88 02) 9827075, 9827077

Email: info@icddr.org

Web: www.icddr.org

External Auditors

A. Qasem & Co.
Chartered Accountants

Senior Leadership Team (SLT)

Mr. Syed Monjurul Islam, Bangladesh (up to Oct 2021)

Deputy Executive Director

Dr. Tahmeed Ahmed, Bangladesh (from Feb 2021)

Senior Director, Nutrition and Clinical Services Division

Dr. Shams El Arifeen, Bangladesh

Senior Director, Maternal & Child Health Division

Dr. Allen Guy Ross, Australia (up to 15 Nov 2021)

Senior Director, Infectious Diseases Division

Dr. Firdausi Qadri (from 1 Dec 2021)

Acting Senior Director, Infectious Diseases Division

Dr. Dinesh Mondal, Bangladesh

Acting Senior Director, Laboratory Sciences Division
and Senior Scientist, NCSD

Dr. Daniel D Reidpath, Australia

Senior Director, Health Systems & Population Studies Division

Dr. S.M. Manzoor Ahmed Hanifi (from Dec 2021)

Scientist, HSPSD

Mr. Thomas Liam Barry, Ireland

Director, Finance

Mr. Hugues Bello, France

Director, Human Resources

Mr. Mohammad Noushad Chowdhury, UK

Director, Supply Chain and Facilities Management

Ms. Armana Ahmed, Bangladesh

Head, Research Administration Service

Observers (SLT)

Mr. Nagarajan Nagarajan, India

Director, Internal Oversight

Mr. Khaja Salauddin Ahmed, Bangladesh (up to August 2021)

Head, Regulatory & Legal Affairs

Mr. Nafiu Alam (from Sep 2021)

Acting Head, Regulatory & Legal Affairs

Mr. A.K.M. Rahmat Ullah (from Dec 2021)

Head, Bio-medical Engineering Unit & RCO

INDEPENDENT AUDITOR'S REPORT
To the Board of Trustees of
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of International Centre for Diarrhoeal Disease Research, Bangladesh ("icddr,b" or "the entity"), which comprise the Statement of financial position as at 31st December 2021, the Statement of activities, Statement of changes in funds and Statement of cash flows for the year 2021 ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the entity as at 31st December 2021, and of its financial performance and its cash flows for the year in accordance with the accounting policies as stated in note 3 to the financial statements.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the entity in accordance with the International Ethics Standards Board for Accountants' *Code of Ethics for Professional Accountants (IESBA Code)* together with the ethical requirements that are relevant to our audit of the financial statements in *Bangladesh*, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in the audit of the financial statements for the year 2021. These matters were addressed in the context of the audit of the financial statements, and in forming the auditor's opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled the responsibilities described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying financial statements.

- **Revenue recognition**

Referring to Note 3.12 and Note 22 to the financial statements, total revenue of USD 80.56 million is recognised in the statement of activities of the entity. The proper identification, measurement and recording of this material item is vital to the financial statements. Recognition of revenue is determined by various important factors like funding conditions of different donors, extent of actual project expenses incurred, recovery from various clinical services, multi-currency transactions to name a few.

How our audit addressed the key audit matters:

- We assessed the entity's processes and controls for recognizing revenue as part of our audit. Our audit approach included testing of the controls and substantive audit procedures.
- We assessed the relevant systems and policies supporting the accounting of revenue.
- Studied the grant agreements/contracts, analyzed conditions and tested invoices and receipts on a sample basis.
- Sought and obtained confirmation from donors regarding contribution received during the year and contribution due as at the reporting date.
- Tested general controls for IT-systems and procedures.
- Assessed the invoicing and measurement systems up to entries in the general ledger.
- Assessed disclosures made in the financial statements for revenue.

Other Information included in the Entity's 2021 Annual Report

Other information consists of the information included in the entity's 2021 Annual Report other than the financial statements and our auditor's report thereon. Management is responsible for the other information. The entity's 2021 Annual Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation of the financial statements in accordance with the accounting policies as stated in note 3 to the financial statements and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.
- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- ▶ Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

A. Qasem & Co.

Chartered Accountants

RJSC Firm Registration No.: 2-PC 7202



Ziaur Rahman Zia, FCA

Partner

Enrolment Number: 1259

DVC: 2206121259AS124359

Place: Dhaka

Date: 12th June 2022

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Statement of Financial Position
as at 31st December 2021

	Notes	Amounts in USD	
		31-Dec-21	31-Dec-20
Non-current assets			
Property, plant and equipment	4	9,958,282	10,626,792
Capital work in progress	5	1,228,423	1,066,232
Assets in transit		-	38,513
Investments	6	19,663,867	17,607,865
Total non-current assets		30,850,572	29,339,402
Current assets			
Inventories	7	352,318	464,201
Accounts receivable	8	16,275,065	13,410,069
Loans and advances	9	4,300,838	3,125,465
Cash and cash equivalents	10	36,511,957	36,403,830
Total current assets		57,440,178	53,403,565
Total assets		88,290,750	82,742,967
Current liabilities			
Deferred contributions	11	25,900,418	29,411,937
Accounts and other payables	12	9,257,201	6,206,725
Provisions	13	9,916,083	8,995,843
Total current liabilities		45,073,702	44,614,505
Total liabilities		45,073,702	44,614,505
Funds			
Hospital endowment fund	14	9,940,172	8,931,348
Centre endowment fund	15	9,723,695	8,676,517
Collateral fund	16	2,004,000	2,004,000
Operating fund	17	11,267,676	14,106,106
CWIP reserve fund	18	59,500	188,486
Revaluation reserve on land	19	4,222,005	4,222,005
Special reserve fund	20	5,000,000	-
Capital investment reserve fund	21	1,000,000	-
Total funds		43,217,048	38,128,462
Total funds and liabilities		88,290,750	82,742,967

Footnotes:

1. Independent Auditor's report in page 2.
2. Notes 1 to 31 are an integral part of these financial statements.

A. Qasem & Co.

Chartered Accountants

RJSC Firm Registration Number: 2-PC 7202



Ziaur Rahman Zia, FCA

Partner


Enrolment Number: 1259

DVC: 2206121259AS124359

Place: Dhaka

Date: 12th June 2022


Director, Finance
icddr,b


Executive Director
icddr,b


Member, Board of Trustees
icddr,b



International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Statement of Activities
for the year ended 31st December 2021

Amounts in USD

Notes	2021 Restricted	2021 Unrestricted	2021 Total	2020 Total
Revenue				
Donor grants	22 64,183,147	7,203,310	71,386,457	56,789,855
Income from labs	107	6,771,151	6,771,258	5,179,503
Rental income	-	28,131	28,131	19,128
Interest income	19	709,730	709,749	583,950
Cafeteria and guest house	5,614	175,976	181,590	143,975
Travellers' clinic service	-	122,889	122,889	173,999
Generator services	-	-	-	1,738
Fixed assets handling charges	-	49,930	49,930	42,482
Other receipts	23 743,955	481,419	1,225,374	1,083,187
Forex gains	-	84,621	84,621	762,833
Total revenue	64,932,842	15,627,157	80,559,999	64,780,650
Expenditure				
Salaries and benefits - local	29,840,075	10,978,839	40,818,914	36,877,177
Salaries and benefits - international	3,150,953	1,519,685	4,670,638	5,306,815
Salaries and benefits emeritus - international	1,123,251	14,897	1,138,148	1,066,100
Salaries and benefits emeritus - national	168,422	-	168,422	161,155
Consultancy fees	511,115	101,349	612,464	616,875
Travel and vehicle hire charges	2,458,021	620,534	3,078,555	2,221,314
Supplies and materials	7,814,047	3,096,372	10,910,419	7,362,999
Repairs and maintenance	394,256	139,354	533,610	383,625
Legal and professional fees	482,905	310,266	793,171	397,815
Rent, communication and utilities	1,217,545	447,496	1,665,041	1,527,927
Printing and publications	355,405	110,900	466,305	389,902
Collaborative partnership costs	4,509,566	-	4,509,566	2,556,204
Training, dissemination and staff development	1,137,043	16,856	1,153,899	790,834
Doubtful debt expenses	-	208,776	208,776	-
Interdepartmental service charges	981,875	(981,875)	-	-
Hospital patient expenses	438,941	36,227	475,168	722,849
Cleaning and security charges	612,295	762,975	1,375,270	1,361,307
Indirect cost charges	6,243,466	(6,243,466)	-	-
Depreciation	3,293,397	1,196,578	4,489,975	2,091,808
Mandatory committee meeting expenses	24 66,966	100,054	167,020	125,931
Research support recovery	19,302	(19,302)	-	-
Other expenditure	25 113,996	53,794	167,790	153,329
Total expenditure	64,932,842	12,470,309	77,403,151	64,113,966
Surplus	-	3,156,848	3,156,848	666,684

Footnotes:

1. Independent Auditor's report in page 2.
2. Notes 1 to 31 are an integral part of these financial statements.

A. Qasem & Co.

Chartered Accountants

RJSC Firm Registration Number: 2-PC 7202



Ziaur Rahman Zia, FCA

Partner


Enrolment Number: 1259

DVC: 2206121259AS124359

Place: Dhaka

Date: 12th June 2022


Director, Finance
icddr,b


Executive Director
icddr,b


Member, Board of Trustees
icddr,b



International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b)
Statement of Changes in Funds
for the year ended 31st December 2021

	Hospital Endowment fund note 14	Centre Endowment fund note 15	Collateral fund note 16	Operating fund note 17	CWIP reserve fund note 18	Revaluation reserve on land note 19	Special Reserve Fund note 20	Capital Investment Reserve Fund note 21	Total
Notes									
Balance as at 1st January 2020	7,957,156	7,607,277	2,004,000	13,421,715	2,074,713	4,222,005			37,286,866
Additions during the period									
Donations received	9,337								9,337
Fund raising expenses during the year	(626)								(626)
Income from fixed rate investments during the year	135,392	94,341	17,707						247,440
Realised gains from equity investment during the year	85,522	96,750							182,272
Unrealised gains from equity investment during the year	744,567	878,149							1,622,716
Surplus for the year 2020				666,684					666,684
Transfers made during the year			(17,707)		(2,032,374)				(2,050,081)
Additions during the period					195,414				195,414
Adjustments made during the year				17,707	(49,267)				(31,560)
Balance as at 31st December 2020	8,931,348	8,676,517	2,004,000	14,106,106	188,486	4,222,005	-	-	38,128,462
Donations received	29,086								29,086
Funds raising expenses during the year	(8,288)								(8,288)
Income during the year	136,147	97,047	4,722						237,916
Realised gains during the year	839,132	1,158,046							1,997,178
Unrealised gains during the year	12,747	(207,915)							(195,168)
Surplus for the year 2021				3,156,848	(188,486)				3,156,848
Transfers made during the year			(4,722)	(6,000,000)	59,500		5,000,000	1,000,000	(193,208)
Additions during the year				4,722					59,500
Adjustments made during the year									4,722
Balance as at 31st December 2021	9,940,172	9,723,695	2,004,000	11,267,676	59,500	4,222,005	5,000,000	1,000,000	43,217,048

Footnotes:

1. Independent Auditor's report in page 2.
2. Notes 1 to 31 are an integral part of these financial statements.

A. Qasem & Co.

Chartered Accountants
 RJSC Firm Registration Number: 2-PC 7202

Ziaur Rahman Zia, FCA

Ziaur Rahman Zia, FCA
 Partner

Enrolment Number: 1259
 DVC: 2206121259AS124359

Place: Dhaka
 Date: 12th June 2022

[Signature]
 Director, Finance
 icddr, b

[Signature]
 Executive Director
 icddr, b

[Signature]
 Member, Board of Trustees
 icddr, b



International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Statement of Cash Flows
for the year ended 31st December 2021

	<i>Amounts in USD</i>	
	2021	2020
Cash flows from operating activities:		
Surplus for the year	3,156,848	666,684
Adjustments to reconcile net cash from operating activities:		
Depreciation	4,489,975	2,091,808
Loss on disposal of assets	902	2,847
Interest income	(709,749)	(583,950)
Income from collateral fund	4,722	17,707
Changes in current assets and liabilities:		
Increase in accounts receivable	(2,821,030)	(3,567,033)
Increase in loans and advances	(1,175,373)	(78,014)
Decrease in inventories	111,883	(112,541)
Decrease in deferred contributions	(3,511,519)	2,441,224
Increase in accounts payable and provisions	3,970,716	147,796
Net cash flows from operating activities	3,517,375	1,026,528
Cash flows from investing activities:		
Investments	(128,986)	(1,886,227)
Capital expenditure	(3,946,045)	(340,522)
Interest received	665,783	603,374
Net cash used in investing activities	(3,409,248)	(1,623,375)
Cash flows from financing activities		
Net cash used in financing activities	-	-
Net increase/(decrease) in cash and cash equivalents	108,127	(596,847)
Cash and cash equivalents as at 1st January	36,403,830	37,000,677
Closing cash and cash equivalents as at 31st December	36,511,957	36,403,830

Footnotes:

1. Independent Auditor's report in page 2.
2. Notes 1 to 31 are an integral part of these financial statements.

A. Qasem & Co.

Chartered Accountants

RJSC Firm Registration Number: 2-PC 7202



Ziaur Rahman Zia, FCA


Partner


Enrolment Number: 1259

DVC: 2206121259AS124359

Place: Dhaka

Date: 12th June 2022


Director, Finance
 icddr,b


Executive Director
 icddr,b


Member, Board of Trustees
 icddr,b



International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Notes to the financial statements
for the year ended 31st December 2021

1 Reporting entity

The International Centre for Diarrhoeal Disease Research, Bangladesh (hereinafter referred to as "icddr,b" or "the entity") was established in 1978 by an Ordinance of the Government of The People's Republic of Bangladesh. Subsequently, the original Ordinance dated 9th December 1978 was amended in 1998 to extend the tenure of icddr,b to 50 years until 2028. The main objective was to provide for the establishment of an international Centre in Bangladesh with multinational scientific collaboration and financial contributions for conducting research in diarrhoeal diseases and directly related subjects of nutrition, fertility and other matters ancillary thereto, with special relevance to developing countries. The activities of icddr,b are funded mainly by various Governments and international organisations.

1.01 Submission of annual tax returns and financial year

icddr,b is an international organisation, and it is exempt from taxes as per the icddr,b Ordinance 1978. As such, the Centre has been maintaining its financial year from January to December and intends to continue maintaining the accounting year from January to December instead of July to June. However, icddr,b has made an application in 2017 to the National Board of Revenue seeking re-confirmation of the status of icddr,b regarding its formal exemption in terms of submission of annual tax returns. As icddr,b didn't receive any formal response yet from the NBR, it has resubmitted another application in 2020.

2 Basis of preparation

2.1 Basis of accounting

icddr,b prepares the financial statements in accordance with stated accounting policies in note 3, which uses the accrual basis of accounting, whereby, the revenue is recognised when earned and expenses recognised when incurred.

icddr,b also prepares the financial statements on a going concern basis, as the entity is viewed as continuing in operations for the foreseeable future. The term 'foreseeable future' is deemed to be a period of at least 12 months from the end of the reporting period.

2.2 Functional and presentation currency

The financial statements of the Centre are presented in US dollars, which is icddr,b's functional and presentational currency and, figures are rounded off to the nearest dollar unless otherwise indicated.

2.3 Use of estimates and judgments

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods that are affected.

In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amount recognised in the financial statements are stated in the following notes:

- Note 4** Depreciation of property, plant and equipment
- Note 8** Provision for doubtful contributions
- Note 13** Provisions

2.4 Reporting period

icddr,b's financial statements covers the accounting period of 12 months from 1st January to 31st December every year and, is followed consistently.

2.5 Components of this complete set of financial statements

The financial statements of the entity comprises a statement of financial position, a statement of activities (disclosing income and expense), a statement of changes in funds, a statement of cash flows and, the notes to the financial statements.

2.6 Functional allocation of expenses

The costs of providing various programs and other activities are summarised by their functional classification in the Statement of Activities and, by their natural classification in the functional expenses are shown in note No. 27 to the financial statements. Accordingly, certain costs are allocated amongst the programs and supporting services that derive benefits from these costs.



3 Significant accounting policies

The significant accounting policies relating to the preparation of these financial statements are described below. These accounting policies have been applied consistently in the preparation and presentation of these financial statements.

3.01 Property, plant and equipment

The details about the treatment, regarding property, plant, and equipment are provided in note No. 4. In addition, inter-departmental charges have been added to the cost of the assets as per the centre's cost recovery policy.

3.01.1 Recognition and measurement

3.01.1.1 Purchased PPE

Items of property, plant and equipment (excluding land) are measured at cost less accumulated depreciation and impairment losses if any. All individual items costing USD 500 and above, that have a useful life of more than one year are capitalised. The cost of an asset comprises its purchase price and all other directly attributable costs incurred to bring the asset to its working condition.

3.01.1.2 Donations in-kind

Donated fixed assets are recorded at fair market value. Donations in-kind inventory is recognised as a revenue and corresponding expenses are accounted for.

3.01.1.3 Freehold Land

Freehold land is recorded at cost. icddr,b made a revaluation of all the freehold land during 2012 and 2013. The revalued amount of these areas of land have been initially recognised in the financial statements during 2013; and accordingly, the Board approved the financial statements of 2013 and 2014, presenting the above areas of land at fair value. Simultaneously, the corresponding revaluation reserve has also been recognised under the Statement of Changes in funds.

3.01.2 Subsequent costs

Subsequent costs are capitalised only when the future economic benefits embodied on the specific assets which they relate, will flow to icddr,b, and the cost of the day-to-day servicing of property, plant and equipment is recognised in the statement of activities as incurred.

3.01.3 Depreciation

Property, plant & equipment acquired through grants:

Depreciation for property, plant and equipment acquired through unrestricted grants is charged to the statement of activities from the month of capitalisation on a straight-line basis over the estimated useful lives of items. In case of disposal, no depreciation is charged in the month of disposal. Depreciation on property, plant and equipment is calculated based on the following estimated useful lives:

	<u>Useful life in years</u>
Building	20
Equipment	5
Furniture & Fittings	7
Computers/Laptops	4
Software	5
Vehicles	5

Property, plant and equipment acquired through restricted grants are recorded as assets and depreciated at the rate of 100% in the year of capitalisation. The depreciation expense is charged directly to the restricted fund in the statement of activities.

3.01.4 Retirements and disposals

An asset is derecognised on disposal or when no future economic benefits are expected from its use and subsequent disposal. For disposal of locally procured fixed assets, a gain or loss arising from the retirement or disposal is determined as the difference between the net disposal proceeds and the carrying amount of the assets. The disposal proceeds from local assets shown as other income and the carrying amount of the asset shown as other expenditure in the statements of activities. In case of disposal of foreign procured fixed assets, the sale proceeds amount is payable to the 'National Board of Revenue', and the carrying amount is reported in the Statement of Activities as expenses.



3.02 Capital work in progress (CWIP)

- (i) Capital work in progress represents the cost incurred to acquire and/or construct items of property, plant and equipment that are not ready for use. CWIP is measured at cost.
- (ii) There are some assets shown under CWIP which have been obtained through restricted grants and, these are charged 100% in the respective project in the year these costs were incurred. These CWIP assets were debited in the CWIP ledger with cost and credited to the CWIP reserve fund ledger for the charge amount, similar to accumulated depreciation. The assets and funds are disclosed under note 5 and 18 respectively.

3.03 Intangible assets

Intangible assets are not presented under a separate line item. These assets are included in equipment and amortised as per icddr,b policy.

3.03.1 Recognition and measurement

An intangible asset is recognised under equipment portion of the fixed assets if it is probable that future economic benefits that are attributable to the asset will flow to icddr,b and the cost of the asset can be measured reliably. An intangible asset is measured initially at cost. After initial recognition, it is carried at cost less accumulated depreciation/amortisation and accumulated impairment losses (if any).

3.03.2 Subsequent costs

Subsequent costs are capitalised only when the future economic benefits embodied in the specific assets which they relate will flow to the icddr,b and the cost of the day-to-day servicing of property, plant and equipment is recognised in the statement of activities as incurred.

3.03.3 Amortisation of intangible assets

An intangible asset acquired through unrestricted grants is amortised to the statement of activities on a straight-line basis over the estimated useful lives of five years from the month of capitalisation.

An intangible asset acquired through restricted grants is amortised to the statement of activities at the rate of 100% in the year of capitalisation.

3.04 Financial assets

3.04.01 Loans and advances

Loans and advances are initially measured at cost i.e., payment value. After initial recognition, these are carried at cost less deductions, adjustments or charges to other account categories such as expenses.

3.04.02 Accounts receivable

Accounts receivable from donors and other entities are carried at the net realisable value calculated as the gross amount less any allowance provided for doubtful receivables.

Receivables under restricted grants are shown as receivable based on the expenses incurred during the year but not reimbursed by the donor at year end. Receivables under unrestricted grants are the amounts which are yet to be received at the year-end as per agreements with donors.

An allowance for doubtful debts is created for receivables believed to be uncollectible after exhausting efforts for realisation. The receivable balance against the provision for doubtful debts is to be written off after receiving approval from the Board of Trustees (BoT).

Receivables from employees are recognised as they arise and adjusted when payment is received.

Interest receivable is recognised when interest is earned, but has not yet been received in cash.

Receivables from other income are recognised when the customers are billed/invoiced.

Receivables under grants are shown as receivables based on the expenses incurred during the year but not reimbursed by the donor at year-end.

The donors are invoiced/billed in line with the terms and conditions laid down in the agreements against the receivables as, the



3.04.03 Time deposits

Time deposits for unrestricted funds are initially measured at cost and subsequently, the income earned is recognised in the Statement of Activities.

Time deposits for restricted funds initially measured at cost and subsequently, the income earned is recognised through Statement of Changes in Funds.

3.04.04 Fixed rate investments

Fixed rate investments deposits (Bonds and Treasury bills) for endowments funds are initially measured at cost and subsequently, the income earned is recognised through Statement of Changes in Funds.

3.04.05 Equity instruments

Equity instruments are related to Endowment funds which are initially measured at cost and subsequently, the realised and unrealised gains are recognised through the Statement of Changes in Funds.

3.05 Impairment

3.05.1 Non-derivative financial assets

Financial assets not carried at fair value through the surplus or deficit i.e. time deposits, loans and receivables are assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if, objective evidence indicates that a loss event has occurred after the initial recognition of the asset and, that the loss event had a negative effect on the estimated future cash flows of that asset can be estimated reliably.

3.05.2 Non-financial assets

The carrying amount of the non-financial assets, other than inventories are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists then the assets' recoverable amounts are estimated. An impairment loss is recognised if the carrying amount of an asset exceeds its estimated recoverable amount.

3.06 Cash and cash equivalents

Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes. For an investment to qualify as a cash equivalent it must be readily convertible to a known amount of cash and be subject to an insignificant risk of changes in value. Therefore, an investment normally qualifies as a cash equivalent, only when it has a short maturity e.g. three months or less from the date of issue.

Cash includes cash on hand and in our banks accounts. Cash equivalents are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity date that they present insignificant risk of changes in value. Cash and cash equivalents also include time deposits (Investment) having a maturity date for less than three (3) months. Any investments which has a maturity term for over 3 month is considered to be a short term investment.

3.07 Leases

Leases of the property where a significant portion of the risks and rewards of ownership is retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the Statement of Activities on a straight-line basis over the period of the lease.

3.08 Inventories

Initial recognition:

Inventories, other than those purchased on requirement for immediate consumption, are valued at invoice price plus incidental expenses such as labour, freight, insurance, etc.

Recognition as expense:

Inventories issued at moving weighted average cost to service centres are expensed when issued.

Measurement at reporting date:

The expired and obsolete inventories are measured at lower of cost and net realisable value. The remaining closing inventories are measured at weighted average cost to service centres.



3.09 Endowment funds

Endowment funds were created out of specific donations received in earlier years. They are governed by the respective by-laws (ref. notes No. 14 & 15). Contributions received are credited to these funds. Endowment funds are invested both in the local and overseas market. Local investment includes shares, time deposits, and overseas market investments are managed by TIAA-CREF Trust company FSB on icddr,b's behalf. Investments are recorded at fair market value.

Income/gains from these investments net of expenses/losses are considered as a contribution and credited to this fund. Interest on investment is recognised on an accrual basis.

3.09.1 Investments

Investments under the endowment funds are valued at market value. The cash amount relates to particular endowment funds is shown under the relevant funds investment category.

3.10 Salaries and benefits

Salaries and benefits to employees are recognised on an accrual basis in accordance with the terms of employment. The cost of benefits to employees in the form of medical reimbursement, group insurance and end of service benefits are based on contractual obligations.

Restricted contributions received against obligations towards end-of term benefits of employees are adjusted against subsequent project expenditure to the extent such obligations exceed actual amount paid or payable on settlement of the obligation. Such contributions pending adjustments are included in the note No. 13 'Provisions'.

Retirement benefits for international staff are managed by The Association of International Agricultural Research Centres (AIARC), an autonomous body providing comprehensive payroll management services to various agricultural research organizations worldwide. Payments to AIARC include defined contributions towards the retirement benefits, which exonerates icddr,b of all further liabilities on this account.

Obligations for contributions in respect of the Provident Fund are recognised as an expense in the statement of activities as incurred with effect from September 2015, the management of icddr,b introduced an approved provident fund for its employees.

icddr,b provides end of service benefits to separated employees under specific provisions of the Staff Regulations and Rules 2012. These benefits are defined planned benefits and it makes provision for the benefit based on its own methodology for calculating the provision for End of Service benefit based on the HR policy whereby, it is mentioned that "the organisation contributes 2% of base pay for local fixed-term staff members every month, and it accumulates it as a "Provision for the End of Service Benefits (ESB)".

3.11 Provisions

Provisions are recognised on the reporting date if, as a result of past events, icddr,b has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.

In some cases due to obligatory donor reporting, we also recognise provisions for some unfinished project related tasks such as audit, publications etc. subject to Donor consent.



3.12 Revenue recognition

Grants are classified according to the type of restrictions attached to them.

Unrestricted grants are grants which icddr,b may freely use for its mandated activities. Restricted grants are grants received in support of specified projects or activities mutually agreed upon by icddr,b and donors. Revenue is recognised to the extent of actual expenses incurred. Contributions (except those pertaining to endowment funds) are considered as revenue on the following basis:

- (i) Unrestricted funds are accounted for to the extent they relate to the current year and those pertaining to future years are carried forward.
- (ii) Revenues from project funds are recognised on the basis of costs directly incurred on projects plus overhead recoveries in accordance with the terms of the related agreements with donors. Project funds received during the year but yet to be expensed are carried forward as contributions received in advance. Correspondingly, project expenses incurred but yet to be reimbursed by the donor are considered as contributions receivable.
- (iii) Awards received for which the Board of Trustees has identified specific usage are accounted for as if these were project funds.
- (iv) Contributions received in kind are included in the financial statements at fair market value.
- (v) Interest on investments is recognised using the time proportion method based on the underlying interest rate.
- (vi) Other revenue is recognised when services are performed. In addition, unspent balances are normally returned to the donor as part of grant close out. However, in some cases, the donor agrees (subject to permission obtained) to support additional activities or allows icddr,b to retain the funds, usually if the balances are small e.g. some donors like BMGF permit retention of the balances which are below the sum of USD 20,000.

3.14 Foreign currency

Transactions in currencies other than the US dollar are recorded at the exchange rates prevailing at the beginning of the month in which the transaction takes place. Exchange differences arising during the year on settlement of transactions in other currencies are recognized in the statement of activities for the year.

All monetary assets and liabilities denominated in other currencies at the reporting date are retranslated to US dollar at the year end exchange rates. The resulting exchange differences arising on translating monetary items at the end of the reporting period are recognized in the statement of activities for the year.

The exchange rates used for the currency conversion are calculated on the prevailing average of the buying rates of 'Telegraphic Transfer Clean' and 'On Demand Transfer' as published by Standard Chartered Bank are as follows:

Currency	Year end Exchange Rates		
	2021	2020	
	Average monthly exchange rate	Year-end rate	Year-end rate
	BDT	BDT	BDT
USD 1.00	83.99	84.60	83.75
UK £1.00	98.33	112.21	100.81
EURO €1.00	114.76	94.64	111.51

3.15 Contingencies

Contingent liability

A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity.

A contingent liability is not recognised, but disclosed in the financial statements under note 30. A provision is recognised in the period in which the recognition criteria of the provision is met.

3.16 Statement of cash flows

Cash flow statements for operating cash are presented under the indirect method.



3.17 Events after the reporting period

Adjusting events are those providing evidence of conditions about icddr,b's financial position existing at the reporting date. Such events are reflected in the financial statements when material. Events after the reporting period that are not adjusting events are disclosed in the notes to the financial statements when material.

3.18 Inter-department charges

icddr,b is charging interdepartmental service charges for various services given to all the projects by support services as part of full cost recovery and in addition to indirect costs.

3.19 Adjustment for changes in accounting policy & prior year's errors:

In the prior years, the required accounting adjustments for changes in accounting policy and prior years' error were made in the year in which they were identified. However, the Centre has adopted a new accounting policy from the year 2020, whereby, any required accounting adjustments for changes in accounting policy and prior years' material errors are to be made retrospectively.

3.20 Submission of annual tax returns and financial year

icddr,b is an international organisation, and it is exempt from taxes as per the icddr,b Ordinance 1978. As such, the Centre has been maintaining its financial year from January to December and intends to continue maintaining the accounting year from January to December instead of July to June. However, icddr,b has made an application in 2017 to the National Board of Revenue seeking re-confirmation of the status of icddr,b regarding its formal exemption in terms of submission of annual tax returns. As icddr,b didn't receive any formal response yet from the NBR, it has resent another application in 2020.

3.21 Accounts payable

The entity recognises a financial liability when its contractual obligations arising from past events are certain and the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits. The carrying amount of the payables is approximate with its fair value due to its short-term nature.

3.22 Deferred contribution

When a contribution is received but not spent, it is deferred on the statement of financial position as a deferred liability until such a time as it is "earned." A contribution is "earned" when the conditions regarding its use are met and the amount is spent.

3.23 Special reserve fund

This reserve was approved by the Board in 2019 in the following resolution "RES/4/F&AC/Nov 2019" - The Board asked Management to create a Special Reserve Fund that would provide for between 6-12 months provision for core operations and essential capital equipment

3.24 Capital Investment Reserve fund

This reserve was approved by the Board in 2021 according to the following resolutions;

"RES/1/F&AC/Nov 2021/FB/Dec 2021" - "The Board approved the 2022 balanced budget with budgeted revenues amounting to US\$ 67 million and a transfer of US\$ 1 million from operating funds to the Capital Reserve Fund for its replenishment."

RES/5/F&AC/FB/Dec 2021 - The Board approved providing for a capital reserve in 2021 and transferring US\$ 1 million from operating funds to the Capital Reserve Fund.

3.25 Operating fund

The operating fund balance is the accumulation of the annual surpluses. In the year when icddr,b shall incur a deficit, the deficit balance shall be adjusted within the operating fund.

3.26 Collateral fund

This fund was established as a reserve fund to enable icddr,b to achieve improved financial stability and, to enable it to retain a satisfactory level of operating activities, in case of an irregular flow of resources beyond its control. However in practice, the entire cash representing this fund has been and continues to be used as collateral against bank Letter of Credit facilities. Currently, it is not accessible for operations, in terms of the facilities agreement with Standard Chartered Bank (note No. 10.2b).



International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b)
Schedule of property, plant and equipment
for the year ended 31st December 2021

4. Property, plant and equipment

Category	Cost					Accumulated depreciation/amortisation				Amounts in USD	
	Balance as at 1st Jan 2021	Additions during the year	Disposals/adjustments during the year	CWIP Assets	Balance as at 31st Dec 2021	Charged during the year	Disposals/adjustments during the year	CWIP Assets	Balance as at 31st Dec 2021	Written down value as at 31st Dec 2021	
Unrestricted											
Freehold land	3,665,914	-	-	-	3,665,914	-	-	-	-	3,665,914	
Buildings (a)	9,501,482	7,966	(28,600)	-	9,480,848	220,211	(28,599)	-	6,100,360	3,380,488	
Equipment (b)	10,992,450	519,035	(54,892)	-	11,456,593	928,921	(54,016)	-	9,311,913	2,144,680	
Furniture	220,384	1,970	-	-	222,354	23,330	-	-	154,242	68,112	
Vehicles	300,803	-	-	-	300,803	24,117	-	-	244,943	55,860	
Sub-total	24,681,033	528,971	(83,492)	-	25,126,512	1,196,579	(82,615)	-	15,811,458	9,315,054	
Restricted											
Freehold land	615,588	-	-	-	615,588	-	-	-	-	615,588	
Land under license/Leasehold land (c)	26,011	-	-	-	26,011	-	-	-	-	26,011	
Buildings	11,853,845	878,455	-	-	12,732,300	878,455	-	-	12,732,292	8	
Equipment	19,061,809	2,419,810	(99,706)	-	21,381,913	2,290,824	(99,688)	-	21,380,377	1,536	
Furniture	23,426	-	-	-	23,426	23,385	-	-	23,385	41	
Vehicles	1,249,900	124,118	(49,733)	-	1,324,285	124,118	(49,726)	-	1,324,241	44	
Sub-total	32,830,579	3,422,383	(149,439)	-	36,103,523	3,293,397	(149,414)	128,986	35,460,295	643,228	
Total 2021	57,511,612	3,951,354	(232,931)	-	61,230,035	4,489,976	(232,029)	128,986	51,271,753	9,958,282	

Category	Cost					Accumulated depreciation/amortisation				Amounts in USD	
	Balance as at 1st Jan 2020	Additions during the year	Disposals/adjustments during the year	CWIP Assets	Balance as at 31st Dec 2020	Charged during the year	Disposals/adjustments during the year	CWIP Assets	Balance as at 31st Dec 2020	Written down value as at 31st Dec 2020	
Unrestricted											
Freehold land	3,665,914	-	-	-	3,665,914	-	-	-	-	3,665,914	
Buildings (a)	8,802,954	814,051	(115,523)	-	9,501,482	221,927	(115,522)	-	5,908,748	3,592,734	
Equipment (b)	9,901,766	1,097,417	(6,733)	-	10,992,450	901,407	(5,801)	-	8,437,008	2,555,442	
Furniture	220,384	-	-	-	220,384	24,455	-	-	130,912	89,472	
Vehicles	315,833	37,215	(52,245)	-	300,803	23,211	(52,240)	-	220,826	79,977	
Sub-total	22,906,851	1,948,683	(174,501)	-	24,681,033	1,171,000	(173,563)	-	14,697,494	9,983,539	
Restricted											
Freehold land	615,588	-	-	-	615,588	-	-	-	-	615,588	
Land under license/Leasehold land (c)	26,011	-	-	-	26,011	-	-	-	-	26,011	
Buildings	10,058,706	1,795,139	-	-	11,853,845	(34,946)	-	-	11,853,837	8	
Equipment	19,078,333	823,035	(839,559)	-	19,061,809	816,161	(839,548)	-	19,060,255	1,594	
Furniture	23,426	-	-	-	23,426	23,385	-	-	23,385	41	
Vehicles	1,108,407	141,493	-	-	1,249,900	139,593	1,898	-	1,249,849	51	
Sub-total	30,910,471	2,759,667	(839,559)	-	32,830,579	920,808	(837,650)	1,836,960	32,187,326	643,253	
Total 2020	53,817,322	4,708,350	(1,014,060)	-	57,511,612	2,091,808	(1,011,213)	1,836,960	46,884,820	10,626,792	

a) Cost of buildings includes an amount of US\$ 210,084 (currently written down value is 1 USD) that was spent by the Centre in earlier years, in respect of the extension of the Institute of Public Health building, which is owned by the Government of the People's Republic of Bangladesh. This building was constructed by the Centre and has been occupied by the Centre since its inception.

b) Equipment includes computer equipment, laboratory and hospital equipment, maintenance equipment, office equipment and software.

c) Land under License /Leasehold Land:

Land under license/Leasehold land includes licensed land of 4.10 acres and Leasehold land of 1.47 acres. Land under license comprises the present icddr, b complex at Mohakhali area in Dhaka. The land under license has not yet been demarcated, but the Centre has applied to the Land and Survey Department of the Peoples Republic of Bangladesh for demarcation of the land.



International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Notes to the financial statements
for the year ended 31st December 2021

4.1 Unserviceable fixed assets

The following unserviceable fixed assets are included in the property, plant and equipment, most of them were procured duty-free from overseas:

31st December 2021	Cost	Amounts in USD Accumulated depreciation	Book value
Equipment	1,003,246	1,002,358	888
Vehicles	86,082	86,075	7
Total	1,089,328	1,088,433	895

31st December 2020	Cost	Amounts in USD Accumulated	Book value
Equipment	675,489	674,825	664
Vehicles	2,602	2,599	3
Total	678,091	677,424	667

The unserviceable fixed assets are to be auctioned after obtaining a necessary approval from the National Board of Revenue.

5 Capital work in progress

	2021 Restricted	2021 Unrestricted	2021 Total	2020 Total
Balance as at 1st January	188,486	877,746	1,066,232	2,912,639
Additions during the year	59,500	291,177	350,677	433,101
Transfers to property, plant and equipment	(188,486)	-	(188,486)	(2,230,241)
Adjustment	-	-	-	(49,267)
Balance as at 31st December	59,500	1,168,923	1,228,423	1,066,232

6 Investments

	2021	2020
Hospital endowment fund investments (note 6.1)	9,940,172	8,931,348
Centre endowment fund investment (note 6.2)	9,723,695	8,676,517
Balance as at 31st December	19,663,867	17,607,865

6.1 Hospital endowment fund investments

	2021	2020
Local investments		
Shares	81,412	82,610
Unrealised gains/(losses) during the year	17,827	(1,198)
	99,239	81,412
Overseas investments		
with TIAA - CREF Trust company FSB	7,561,413	6,650,055
Add: Fixed Income during the year	89,359	80,089
Realised gains during the year	839,132	85,522
Unrealised gains/(losses) during the year	(5,186)	745,747
	8,484,718	7,561,413
Time deposits	1,259,180	1,222,384
	9,743,898	8,783,797
Total investments	9,843,137	8,865,209
Cash at bank	97,035	66,139
Balance as at 31st December	9,940,172	8,931,348

The investments are related to Hospital Endowment Fund (note 14) which was created in 1991. The investments are monitored by the Centre Fund Investment Committee and are invested in the money market, equity mutual funds and fixed income mutual funds. The overseas investment is managed by TIAA - CREF Trust Company USA, and the local investment is in Time Deposits with Bank Asia Limited, Dhaka Bank Limited, Agrani Bank Limited, Standard Chartered Bank, Dhaka and shares in listed companies in Bangladesh.



6.2 Centre endowment fund investments

	<i>Amounts in USD</i>	
	2021	2020
Overseas investments		
With TIAA - CREF Trust Company FSB - at fair market value	8,676,518	7,607,277
Add: Fixed Income during the year	97,047	94,341
Realised gains	1,158,046	96,750
Unrealised gains/(losses) during the year	(207,916)	878,149
Balance as at 31st December	9,723,695	8,676,517

The investments are related to the Centre endowment fund (note 15), which was established in 1996. The Centre Fund Investment Committee monitors the investments. Included in these funds is a USAID contribution of USD 1,000,000 [Market Value 2021: USD 4,656,989; 2020: USD 4,151,382].

7 Inventories

	<i>Amounts in USD</i>	
	2021	2020
Supply stores	318,736	404,503
Maintenance stores	20,328	28,168
Donation in kind	13,254	31,530
Balance as at 31st December	352,318	464,201

Donation in Kind includes medicine received as a donation, this is not yet consumed and is therefore, treated as a deferred contribution.

8 Accounts receivable

	<i>Amounts in USD</i>	
	2021	2020
Donors' receivables		
Restricted (note 8.1)	16,880,398	13,878,854
Unrestricted (note 8.2)	-	2,399
	16,880,398	13,881,253
Less: Provision for doubtful contributions	723,456	524,657
	16,156,942	13,356,596
Other receivables		
Add: Accrued interest on time deposits	97,439	53,473
Add: Accrued other Income	20,684	-
Balance as at 31st December	16,275,065	13,410,069

8.1 Accounts receivable - Restricted

	<i>Amounts in USD</i>	
	2021	2020
Bill & Melinda Gates Foundation	4,395,516	2,468,352
Government of the People's Republic of Bangladesh (GoB)	138,051	360,336
Global Affairs Canada (GAC)	112,668	112,668
Government of Japan	376,228	122,797
Grand Challenges Canada (GCC)	1	38,145
Joint Funding	673,443	465,497
Swedish International Development Cooperation Agency (Sida)	72,238	90,796
The Commission of the European Communities	775,671	1,884,690
The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)	708,279	221,560
The Wellcome Trust	24,676	10,985
The World Bank	115,422	41,527
Foreign, Commonwealth & Development Office (FCDO)	78,660	594,564
United Nations Development Group (UNDG)	1,442,900	852,815
United States Government (USG)-Others	148,489	53,204
USA - Other than USG	694,831	389,773
USG - Centers for Disease Control and Prevention (CDC)	828,939	692,239
USG- National Institute of Health (NIH)	1,337,048	1,561,613
USG - United States Agency for International Development (USAID)	1,654,383	1,168,879
Others	3,302,955	2,748,414
	16,880,398	13,878,854

*Department for International Development (DFID) was renamed as Foreign, Commonwealth & Development Office (FCDO) during Sept 2020.



8.2 Accounts receivable - Unrestricted

Swedish International Development Cooperation Agency (Sida)
Balance as at 31st December

Amounts in USD
2021 **2020**

-	2,399
-	2,399

9 Loans and advances

Loans and advances to employees
Investment loans
Others

Advances to suppliers and others
Balance as at 31st December

Amounts in USD
2021 **2020**

23,545	26,618
232,176	225,660
255,721	252,278
4,045,117	2,873,187
4,300,838	3,125,465

10 Cash and cash equivalents:

Short term investments (note 10.1)
Cash and cash equivalents (note 10.2)
Balance as at 31st December

Amounts in USD
2021 **2020**

9,077,109	4,925,458
27,434,848	31,478,372
36,511,957	36,403,830

(a)

10.1 Short Term Investments

Taka accounts
USD accounts
Collateral accounts

Balance as at 31st December

Amounts in USD
2021 **2020**

4,253,562	98,494
2,699,062	2,707,202
2,124,485	2,119,762
9,077,109	4,925,458

(b)

10.2 Cash and cash equivalents

Cash in hand

Cash at banks:

Taka accounts:

Current account
Time deposits

USD accounts:

Current account
Time deposits

EURO current account:

UK£ accounts:

Current account

Time deposits against bank collateral

Balance as at 31st December

Amounts in USD
2021 **2020**

1,553	1,695
4,072,434	9,411,880
8,920,145	4,368,163
7,310,472	9,844,614
2,752,372	6,574,750
2,570	2,662
4,365,320	1,265,239
9,982	9,369
27,434,848	31,478,372

(b)

(a) The total cash and cash equivalent balances includes Unrestricted operating funds US\$ 21,240,290, Restricted funds US\$ 13,137,200 and Reserve funds US\$ 2,134,467

(b) Time deposits against bank collateral amount of US\$ 2,134,467 includes US\$ 1.5 million under lien with the bank to the extent of the overdraft facility.

11 Deferred contributions

Restricted (note 11.1)
Unrestricted (note 11.2)
Balance as at 31st December

Amounts in USD
2021 **2020**

21,110,163	21,679,522
4,790,255	7,732,415
25,900,418	29,411,937



11.1 Restricted deferred contributions

	<i>Amounts in USD</i>	
	2021	2020
Bill & Melinda Gates Foundation	4,247,949	6,337,445
Government of The Netherlands	7,284	7,284
Conrad N. Hilton Humanitarian Prize*	1,483,233	1,685,333
Government of Japan	28,643	308,880
Government of the People's Republic of Bangladesh (GoB)	388,907	1,509,303
Global Affairs Canada (GAC)	4,331,437	979,331
Joint Funding	42,798	188,810
The Commission of the European Communities	90,545	63,822
The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)	280,461	178,481
The Swedish International Development Cooperation Agency (Sida)	711,544	1,232,909
The Wellcome Trust	-	1,912
The World Bank	-	18,977
Foreign, Commonwealth & Development Office (FCDO)	174,966	26,985
United Nations Development Group (UNDG)	515,028	1,036,721
USA - Other than USG	655,685	577,213
USG - United States Agency for International Development (USAID)	43,734	379
United States Government (USG)-Other	23,251	21,981
USG - United States Department of Agriculture (USDA)	772,587	1,710,224
USG-National Institute of Health (NIH)	6,420	4,679
Others	7,305,691	5,788,853
Balance as at 31st December	21,110,163	21,679,522

11.2 Unrestricted deferred contributions

	<i>Amounts in USD</i>	
	2021	2020
Government of the People's Republic of Bangladesh (GoB)	456,062	-
Foreign, Commonwealth & Development Office (FCDO)	891,288	2,156,302
Global Affairs Canada (GAC)	3,442,905	5,576,113
Balance as at 31st December	4,790,255	7,732,415

12 Accounts and other payables

	<i>Amounts in USD</i>	
	2021	2020
*Supplies, materials and services	4,913,674	2,773,742
Tax liabilities	4,091,152	3,193,233
Security and other deposits	252,375	239,750
Balance as at 31st December	9,257,201	6,206,725

* The 2020 amount for Supplies, materials and services and the Provision for bad debts under Note 13, have been reclassified to be comparable with the current year's presentation.

13 Provisions

	<i>Amounts in USD</i>	
	2021	2020
Staff allowances provisions	2,748,034	2,409,617
Staff end of service provisions	5,681,204	4,781,248
Provision for audit fees	39,025	39,025
Provision for project activities	1,447,820	1,765,953
Balance as at 31st December	9,916,083	8,995,843



14 Hospital endowment fund

	<i>Amounts in USD</i>	
	2021	2020
Balance as at 1 January	8,931,348	7,957,156
Add: Fund raising expenses during the year	(8,288)	(626)
Donations received	29,086	9,337
Fixed income during the year	136,147	135,392
Realised gains during the year	839,132	85,522
Unrealised gains/(Losses) during the year	12,747	744,567
Balance as at 31st December	9,940,172	8,931,348

The Hospital Endowment Fund was created in 1991 to provide support for patient care at icddr,b hospitals. The related investments are described in note 6.1. Between 1996 and 2017, a total of USD 5.2 million was transferred to the Operating fund for use by Hospital operations which was approved by the Board of Trustees.

15 Centre endowment fund

	<i>Amounts in USD</i>	
	2021	2020
Balance as at 1st January	8,676,518	7,607,277
Add: Fixed income during the year	97,047	94,341
Realised gains during the year	1,158,046	96,750
Unrealised gains/(losses) during the year	(207,916)	878,149
Balance as at 31st December	9,723,695	8,676,517

The icddr,b Centre Endowment fund was established in 1996 to raise donations from governments, government agencies, foundations, corporations and individuals to support new research initiatives and the Centre's ongoing activities. The related investments are described in note No. 6.2. Between 2000 and 2017, a total of USD 1.8 million was transferred to the Operating fund for Centre operations which was approved by the Board of Trustees.

16 Collateral fund

	<i>Amounts in USD</i>	
	2021	2020
Balance as at 1st January	2,004,000	2,004,000
Add: Income during the year	4,722	17,707
	2,008,722	2,021,707
Less: Transferred to operating fund	4,722	17,707
Balance as at 31st December	2,004,000	2,004,000

The fund was established in 1982 as a Reserve fund to enable icddr,b to achieve improved financial stability and, to enable it to retain a satisfactory level of operating activities, in case of an uneven flow of resources beyond its control. However in practice, the entire cash representing this fund has been and continue to be used as collateral against bank facilities. It is not accessible for operations, in terms of the facilities agreement with Standard Chartered Bank (note No. 10b). The cash on time deposits in 2021 earned USD 4,722 as an investment income at an average interest rate of 0.24%.

17 Operating fund

	<i>Amounts in USD</i>	
	2021	2020
Balance as at 1st January	14,106,106	13,421,715
Surplus for the year	3,156,848	666,684
Transfer to Special Reserve Fund	(5,000,000)	-
Transfer to Capital Investment Reserve Fund	(1,000,000)	-
Adjustment for the year	4,722	17,707
Balance as at 31st December	11,267,676	14,106,106

18 CWIP reserve fund

	<i>Amounts in USD</i>	
	2021	2020
Balance as at 1st January	188,486	2,074,713
Additions during the year	59,500	195,414
Transfer to property, plant and equipment	(188,486)	(2,032,374)
Adjustment	-	(49,267)
Balance as at 31st December	59,500	188,486



19 Revaluation reserve on land

	Amounts in USD	
	2021	2020
Balance as at 1st January	4,222,005	4,222,005
Adjustment during the year	-	-
Balance as at 31st December *	4,222,005	4,222,005

*This amount of \$4.2m only includes the freehold land assets. Please refer to Note 3.01.1.3 for further details

20 Special Reserve Fund

	Amounts in USD	
	2021	2020
Balance as at 1st January	-	-
Transferred from operating fund	5,000,000	-
Balance as at 31st December	5,000,000	-

21 Capital Investment Reserve Fund

	Amounts in USD	
	2021	2020
Balance as at 1st January	-	-
Transferred from operating fund	1,000,000	-
Balance as at 31st December	1,000,000	-

22 Donor grants

	Amounts in USD				
	2021 (Due)/ Advanced 1 Jan 2021	2021 Received during the year	2021 (Due)/ Advanced 31 Dec 2021	2021 Income during the year	2020 Income during the year
Unrestricted (note No. 22.1)	7,730,017	4,263,548	4,790,255	7,203,310	8,307,880
Restricted (note No. 22.2)	7,804,277	60,612,046	4,233,176	64,183,147	48,486,015
Total contributions	15,534,294	64,875,594	9,023,431	71,386,457	56,793,895

22.1 Unrestricted

	Amounts in USD				
Donors	2021 (Due)/ Advanced 1 Jan 2021	2021 Received during the year	2021 (Due)/ Advanced 31 Dec 2021	2021 Income during the year	2020 Income during the year
Global Affairs Canada (GAC)	5,576,113	795,949	3,442,906	2,929,156	3,338,942
Government of the People's Republic of Bangladesh (GoB)	-	2,509,969	456,062	2,053,907	1,801,858
Hilton Foundation, USA	-	-	-	-	100,000
The Swedish International Development Cooperation Agency (Sida)	(2,398)	-	-	(2,398)	-
Foreign, Commonwealth & Development Office (FCDO)	2,156,302	957,630	891,287	2,222,645	3,067,080
Total contributions	7,730,017	4,263,548	4,790,255	7,203,310	8,307,880

22.2 Restricted

	Amounts in USD				
Donors	2021 (Due)/ Advanced 1 Jan 2021	2021 Received during the year	2021 (Due)/ Advanced 31 Dec 2021	2021 Income during the year	2020 Income during the year
Bill & Melinda Gates Foundation	3,869,091	9,897,569	(147,567)	13,914,227	11,951,158
Conrad N. Hilton Humanitarian Prize*	1,685,333	2,680	1,483,233	204,780	226,777
Global Affairs Canada (GAC)	866,664	4,620,419	4,218,768	1,268,315	209,698
Government of Japan	186,082	686,504	(347,585)	1,220,171	611,071
Government of The Netherlands	7,284	-	7,284	-	(1,987)
Government of the People's Republic of Bangladesh (GoB)	1,148,964	(451,935)	250,855	446,174	333,992
Grand Challenges Canada (GCC)	(38,144)	62,610	-	24,466	57,672
Joint Funding	(276,686)	1,309,571	(630,647)	1,663,532	1,000,971
The Commission of the European Communities	(1,820,868)	1,698,935	(685,128)	563,195	1,059,491
The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)	(43,078)	2,266,445	(427,817)	2,651,184	3,081,065
The Swedish International Development Cooperation Agency (Sida)	1,142,111	1,457,122	639,304	1,959,929	2,276,744
The Wellcome Trust	(9,073)	23,386	(24,677)	38,990	10,985
The World Bank	(22,550)	305,923	(115,423)	398,796	249,200
Foreign, Commonwealth & Development Office (FCDO)	(567,581)	2,271,274	96,301	1,607,392	1,608,902
United Nations Development Group (UNDG)	183,902	4,390,360	(927,873)	5,502,135	3,922,472
United States Government (USG)-Other	(31,223)	62,805	(125,238)	156,820	266,810
USA - Other than USG	187,442	1,716,026	(39,142)	1,942,610	1,710,104
USG - Centers for Disease Control and Prevention (CDC)	(692,238)	4,580,776	(828,939)	4,717,477	3,052,994
USG - United States Agency for International Development (USAID)	(1,168,500)	11,132,647	(1,610,651)	11,574,798	5,947,854
USG - United States Department of Agriculture (USDA)	1,710,223	-	772,587	937,636	49,237
USG-National Institute of Health (NIH)	(1,556,934)	2,698,002	(1,330,623)	2,471,691	2,106,692
Other contributions (net) (Note 22.2.1)	3,044,056	11,880,927	4,006,154	10,918,829	8,754,113
Total project funds	7,804,277	60,612,046	4,233,176	64,183,147	48,486,015



22.2.1 Other contributions

SL	Name of Donor	Amounts in USD	
		2021	2020
1	Acme laboratories Ltd. Bangladesh	-	27,166
2	Advanced Chemical Industries Limited (ACI), Bangladesh	38,237	61,279
3	Annexon, Inc	1,040,423	545,257
4	ANRS Maladies infectieuses émergentes, Agence autonome de l'Inserm	19,171	-
5	Aria Foods Amba	(383)	38,997
6	Asian Development Bank	7,991	45,987
7	AXIS Clinicals Ltd., India	-	10,028
8	Beximco Pharmaceuticals Ltd.	11,988	216,336
9	BRAC, Bangladesh	43,019	38,137
10	CARE Bangladesh	4,991	102,318
11	CARE, USA	149,953	34,086
12	Charite - Universitaetsmedizin Berlin	11,682	19,944
13	Coalition for Epidemic Preparedness Innovations	212,284	1,538
14	Dalhousie University	15,454	-
15	Dhaka Shishu Hospital	90,816	206,921
16	Dhaka Water Supply and Sewerage Authority (DWASA)	5,173	4,116
17	Drugs for Neglected Diseases Initiative (DNDI), Switzerland	142	65,433
18	EAWAG, Switzerland	31,068	16,009
19	Elanco Bangladesh Limited	2,286	-
20	Environment & Infrastructure Management Solution (EIMS) Ltd.	6,847	-
21	Evotec International GmbH	952	50,720
22	Foundation for Innovative New Diagnostics (FIND), Switzerland	9,475	2,074
23	Foundation Merieux, France	2,602	15,483
24	General Pharmaceuticals Ltd.	33,723	19,314
25	German Doctors e.V.	172,120	58,812
26	GlaxoSmithKline (gsk)	830,329	325,000
27	Gonoshasthaya Pharmaceuticals Limited	22,551	-
28	Green Tree International, Korea	-	1,582
29	Harvard TH Chan School of Public Health, USA	19,622	-
30	HDT Bio Corp	16,212	52,740
31	HKG epi THERAPEUTICS Ltd.	7,893	2,686
32	Healthcare Pharmaceuticals Limited (HPL), Bangladesh	2,551	18,421
33	Heidelberg University Hospital	-	16,719
34	HSBC Bangladesh	17,794	11,337
35	Incepta Pharmaceuticals Ltd. Bangladesh	254,226	-
36	Imperial College of Science, Technology and Medicine, UK	2,478	9,556
37	Infectious Disease Research Institute (IDRI), USA	-	(32,114)
38	Institute for Developing Science and Health Initiatives (IdeSHI), Bangladesh	-	1,916
39	Institute of Epidemiology, Disease Control and Research (IEDCR), Bangladesh	12,837	-
40	Institute of Development Studies (IDS), UK	-	37,591
41	Institute of Medical Biology Chinese Academy of Medical Sciences (IMBCAMS)	35,570	18,044
42	InTec PRODUCTS, Inc.	93,591	21,635
43	International Atomic Energy Agency (IAEA), Austria	19,373	13,249
44	INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (ICGEB)	90	-
45	Ipas, USA	27,260	-
46	International Union for the Scientific Study of Population (IUSSP)	-	5,000
47	IQVIA RDS (INDIA) PRIVATE LIMITED	-	60,021
48	International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B)	98,347	262,396
49	Islamic Development Bank (IDB), KSA	318,430	118,667
50	James P Grant School of Public Health, BRAC University, Dhaka	20,429	1,949
51	Karolinska Institute, Sweden	156,053	-
52	Katholieke Universiteit Leuven (KU LEUVEN RESEARCH & DEVELOPMENT)	16,574	5,645
53	Koninklijk Instituut voor de Tropen (KIT Royal Tropical Institute)	10,008	-
54	Leland Stanford Junior University, USA	169,626	166,824
55	London School of Hygiene & Tropical Medicine	15,658	102,411
56	Max Foundation Bangladesh	12,880	-
57	Max-Planck-Gesellschaft, Germany	47,580	53,412
58	Medical Research Council (MRC), UK	20,128	21,092
59	Médecins Sans Frontières, Spain	11,995	1,083
60	MIT SOLVE	32,070	-
61	Monash University	24,256	-
62	Menzies School of Health Research, Australia	-	7,283
63	Nestec Ltd., Switzerland	(36)	112,483
64	Nestle Foundation, Switzerland	2,782	28,846
65	Norwegian Institute of Public Health (NIPH)	277,738	283,787
66	NUTRITION INTERNATIONAL (NI), Canada	8,094	38,232
67	Orebro University Hospital	126,747	129,449
68	OXFAM, Bangladesh	205,659	124,440
69	Plan International, Bangladesh	26,687	42,299
70	Reproductive Health Services Training and Education Program (RHSTEP)	8,641	-



SL	Name of Donor	Amounts in USD	
		2021	2020
71	Porticus	-	41,592
72	Research Triangle Institute, USA	-	48,744
73	Royal College of Obstetricians and Gynaecologists (RCOG)	-	9,767
74	S K Bioscience	-	460,165
75	Serum Institute of India Private Limited	395,203	275
76	Sight and Life, Switzerland	9,740	19,647
77	Sinovac Biotech Co., Ltd.	28,009	186,808
78	Sinovac Life Sciences Co., Ltd., China	(1)	334,269
79	Staldson (Beijing) Biopharmaceuticals Co., Ltd.	1,002,833	-
80	Stiftung Auxillium (advised by Porticus)	97,893	-
81	Stockholm University, Sweden	35,374	72,523
82	TAC International Inc. Japan	37,758	-
83	Terre des hommes Foundation, Bangladesh	-	9,123
84	The Children's Investment Fund Foundation, UK	187,827	90,717
85	The Hospital for Sick Children, Canada	64,603	17,285
86	The Pirbright Institute, UK	99,049	-
87	The George Institute for Global Health, Australia	-	1,157
88	The Korea International Cooperation Agency (KOICA)	-	(14)
89	The Regents of the University of California	-	2,267
90	The Swiss Tropical and Public Health Institute, Switzerland	-	5,625
91	The University Court of the University of Edinburgh	239,788	124,645
92	The University of Birmingham, United Kingdom	-	(66)
93	The University of Greenwich	-	12,892
94	The University of Melbourne, Australia	2,060	284,817
95	The University of Sheffield, UK	101,061	99,898
96	The University of York	38,168	43,333
97	The Walter and Eliza Hall Institute of Medical research	10,643	50,594
98	Tres Cantos Open Lab Foundation	22,448	-
99	UBS Optimus Foundation, Switzerland	54,378	82,086
100	Université de Neuchatel, Switzerland	12,538	-
101	University of Alberta, Canada	-	140
102	University of Bergen, c/o Department of Clinical Science	344,115	562,672
103	University of Cambridge, UK	691,797	328,234
104	University of Heidelberg, Germany	-	(191)
105	University of Iceland	-	17,128
106	University of New South Wales (UNSW), Sydney, Australia	1,302	4,640
107	University of Newcastle upon Tyne, UK	23,595	14,943
108	University of Notre Dame, USA	6,780	22,117
109	University of Nottingham	(51)	83,285
110	University of Oxford	149,289	45,816
111	University of Sydney, Australia	779,712	369,967
112	University of Tsukuba, Japan	8,251	-
113	University of Technology, Sydney	-	19,115
114	University of Virginia, USA	-	88,390
115	University of Warwick	27,767	19,190
116	Uppsala University, Sweden	(28,205)	110,259
117	USAMC-AFRIMS, Thailand	162,028	103,747
118	Urban Primary Health Care Services Delivery Project- II (UPHCSDP-II), MoLGDR&C, GOB	158,103	54,100
119	Vital Strategies Health Systems (Asia Pacific) Limited ("Vital Strategies")	40,479	-
120	WaterAid in Bangladesh	-	30,447
121	Water and Sanitation for Urban Poor, UK	38,293	33,265
122	Wageningen University & Research	11,366	13,888
123	Western Sydney University, Australia	-	17,882
124	Other donors and Self Sustaining Units	(454,880)	606,639
125	Donation in kind (Note 22.2.1.1)	1,636,979	562,615
Total other contributions		10,918,829	8,750,073



22.2.1.1 Donations in kind

SL	Name of Donor	Amounts in USD	
		2021	2020
1	AALTO SCIENTIFIC LTD	1	-
2	Ace Glove (M) SDN	-	10
3	ACI PHARMACEUTICALS	52	558
4	American Type Culture Collect	-	30
5	Ananta Germents	742	-
6	ATCC, USA	10	30
7	BERKELEY AIR MONITORING GROUP	20,298	-
8	Beximco Pharmaceuticals	4,197	107
9	BGMEA	-	1,056
10	Bill & Melinda Gates Foundation, USA	5	-
11	Bio Rad Laboratories Inc . France	-	150
12	Boston Children's Hospital, USA	145	99
13	CDC, Atlanta, USA	241	49
14	CDC, FLORIDA, USA	-	20
15	Cellabs Pty Ltd Australia	20	-
16	Center for Global Child Health	-	7,138
17	Cepheid SAS, USA	-	15,251
18	Chulalongkorn University, Thailand	520	-
19	Colleen Dzwonek, USA	1	-
20	Colorado State University , USA	-	530
21	CTK Biotech Inc USA	813	205
22	Dacathalon	21	563
23	Dat Viet Trading & Technical Services Co., Ltd.	6	-
24	Delta Pharma Ltd.	427	51
25	Diagnosearch Lifesciences	2,408	-
26	Diane Hicks, USA	-	220
27	Duke University	-	100
28	ECOHEALTH ALLIANCE	17,526	-
29	EMMES Services Pvt Ltd	50	-
30	Emory Global Health Institute	1,200	-
31	Emory University, USA	-	727
32	Entrinsic Bioscience LLC, USA	44,474	-
33	ESCO	-	1,296
34	Evelique Biotechnologies GmbH	13	-
35	Evolve Bio Systems Inc., USA	-	10
36	FICCI	-	10
37	FIND Switzerland	22,800	150
38	Fisher Bio Services, USA	-	860
39	Fisher Biopharma Services India Pvt Ltd	-	1,199
40	Florent Lassalle, UK	1,005	-
41	Fondation Merleux , France	1,352	11,832
42	Genotypic Technologies	-	2,030
43	GenScript (Hong Kong) Limited	644	-
44	Genscript USA Inc	-	100
45	Glaxosmithkline Pharmaceuticals	73,950	2,425
46	Global Drug Facility	187,824	44,510
47	Global Ties for Children Research Center	2,787	4,888
48	Globar Toes Research Center	-	1,125
49	GSK, India	-	79
50	HDT Bio, USA	2,627	-
51	HKG-epi-Therapeutics Ltd	1	-
52	Illumina Singapore Pte Ltd	146,610	-
53	India Institute of Science	-	10
54	INSERM, Nantes, France	10	-
55	Institute of Immunity Transplantation and Infection	1,002	-
56	Intec Products Inc.	435	30
57	Intergrated DNA Technologies Pte Ltd	-	109
58	Johns Hopkins Bloomberg School of Public Health	12,174	-
59	Johns Hopkins University, USA	43,942	19,036
60	Kalon Biological Ltd	-	13
61	Kossan International SDN BHD, Malaysia	-	-
62	Lab Connect, Inc USA	402	354
63	Lajolla Institute	-	1
64	Life Technologies Holding Pte. Ltd.	35	-
65	Maccura Biotechnology Co. Ltd	-	2,433
66	Marks & Spencer	-	20
67	Massachusetts General Hospital	5,241	85
68	Mayland Technologies LLC	2	-
69	Medecins Sans Frontieres	27,168	36,960
70	Megan McDonough, MPH, USA	-	60
71	Montana State University, USA	-	4,809
72	NANTONG FORTUNE GLOBAL TRADING CO., LTD	1,820	-
73	National Institute of Standards and Technology	38	-
74	NAVANA Group	-	5,970



SL	Name of Donor	Amounts in USD	
		2021	2020
75	Nestec Ltd, Switzerland	10	-
76	Nexelis	-	10
77	NEXELIS, BELGIUM	25	-
78	NEXELIS, CANADA	160	-
79	NIH, USA	-	2,854
80	NIST, USA	-	20
81	Norwegian Institute of Public	317	23,502
82	Nova Biomedical.USA	135	-
83	Omnivis Ltd	2,076	-
84	Oxford Nanopore Technologies Ltd	-	2,544
85	Paragon Group	-	4,776
86	Parexel International Clinical Research	13	530
87	Path, USA	9,739	-
88	Pirbright Institute, UK	20	-
89	PM Separations	-	14,275
90	PT BIO-FARMA	-	85
91	PT BIO-FARMA(PERSERO)	7,450	-
92	PT Shipping	28	6
93	Q Squared Solutions Czech Republic	-	873
94	Q2 Solutions	764	1,277
95	Q2 Solutions, CZECH REPUBLIC	-	841
96	Qiagen GmbH	157	-
97	RFL Ltd (Get Well)	126	16
98	RTI International USA	70,670	1,830
99	Saif Powertech Ltd.	1,820	-
100	Sapient BioanalyticS	700	-
101	SD BIOSENSOR, INC, Korea	-	215
102	Sentry Biopharma Services, Inc	102	204
103	Serum Institute Of India	390	1,164
104	Seveillar Clinical Supplies Private Limited, India	15,726	-
105	Sick Kids Canada	-	948
106	Sikh gurdwara OF San Jose, USA	13,750	-
107	Sinovac Biotec Co.	1	-
108	Smart Air	192	6
109	Songhong Chaina	-	4
110	St. Johns Research Institute, India	-	20
111	Staidson (Beijing) Biopharmaceuticals. Ltd	50,505	-
112	Stanford University, USA	100	40,652
113	Stockholm's University	-	376
114	Swiss TPH, Switzerland	1,154	-
115	The Emmes Corporation	116	-
116	The Hospital for Sick Children, Canada	60,951	3,263
117	The Institution Of Engineering	34	-
118	The University of Aberdeen, UK	-	43
119	The University of Melbourne Australia	227	-
120	The University of New Mexico, USA	-	2,860
121	The University of Sheffield UK	99	245
122	The University of Toronto, Canada	-	3,199
123	Translational Health Science	-	10
124	UNICEF	359,885	-
125	Uniformed Services University, USA	11	-
126	Unilever Bangladesh Limited	10,701	1,354
127	United Nations Children's Fund, Denmark	-	-
128	UNITED STATES DEPARTMENT OF AGRICULTURE USDA	-	50
129	University Children's Hospital Zurich	11	-
130	University of Auckland	20,257	-
131	University of Bergen, Norway	8,665	7,705
132	University of Blvd Manassas, USA	10	-
133	UNIVERSITY OF CALIFORNIA USA	9,594	20
134	University of Cambridge, UK	-	33,758
135	University of Colorado School of Medicine, USA	-	100
136	University of Florida, USA	-	740
137	University of Greenwich USA	-	900
138	University of Iceland	100	-
139	University of Illinois Chicago	2,896	-
140	University of Leipzin	1,084	9,160
141	University of Maryland, USA	-	480
142	University of Melbourne	7,875	-
143	University of Notre Dame, USA	-	1,016
144	University of Oxford, UK	-	45,493
145	University Of Sydney, Australia	3,740	-
146	University of Toronto	510	-
147	University of Tsukuba ,Japan	2,310	-
148	University of Vermont	5,208	-



Sl	Name of Donor	Amounts in USD	
		2021	2020
149	University of Virginia, USA	277,200	114,817
150	University of Washington	316	14,299
151	UNOPS	-	52,500
152	Uppsala University	1,418	-
153	USDA-ARS-WHNR, USA	700	310
154	VWR INTERNATIONAL, LLC	289	-
155	Walton	-	981
156	Washington State University	65	-
157	Wellcome Sanger Institute, UK	23,091	1,509
158	WHO, Switzerland	8,592	2,998
159	WHO, UK	-	12
160	Woodley Trial Solutions, UK	-	334
161	WuXi Clinical, USA	-	133
162	WUXI NEST BIOTECHNOLOGY CO. LTD, CHINA	5	-
163	Xiamen Innovax Biotech Co. Ltd.	28,500	-
164	Yale University	1,350	-
Total donations in kind		1,636,979	562,615

23 Other receipts

	Amounts in USD			
	2021 Restricted	2021 Unrestricted	2021 Total	2020 Total
Receipts from X- Ray Tests	-	49,899	49,899	28,480
Receipts Animal Resources	-	-	-	-
Receipts Library Subscriptions	-	35	35	47
Receipts from Attached Car	-	2,403	2,403	1,101
Mortuary Services	-	59	59	107
Self Sustaining	741,370	5	741,375	509,297
Income-contracts, agreement & others.	-	-	-	1,911
Refund of Tax, VAT and others	-	23,789	23,789	-
Photo Printing - AV Services	-	-	-	44
Day Care Services	-	-	-	1,801
Sale of Unserviceable Goods	-	10,079	10,079	6,654
Miscellaneous Receipts	2,528	265,678	268,206	445,254
Receipts from Sale of Tender	-	2,004	2,004	-
Receipt from Endowment Fund	-	-	-	-
Receipts Personal use of Vehicle	-	100,698	100,698	52,400
Receipts from Staff Clinic	-	-	-	-
Training and Seminar	-	9,229	9,229	31,153
Hospital Appeal Fund	-	12,121	12,121	4,729
Salary and Consultancy	-	1,800	1,800	209
ESPF Partial Withdrawal Fee	-	3,620	3,620	-
Receipts from Photocopy Ser.	57	-	57	-
Total	743,955	481,419	1,225,374	1,083,187

24 Mandatory committee meeting expenses

Mandatory committees expenditure includes an aggregate amount of USD 83,200 out of total USD 167,020 (2020: USD 51,600 out of total USD 125,931) paid as honorarium to the Board of Trustee members.

25 Other expenditure

	Amount in USD			
	2021 Restricted	2021 Unrestricted	2021 Total	2020 Total
Washing and laundry charges	2,182	594	2,776	2,633
Decorator and outside catering	2,394	244	2,638	20,265
Membership and subscription for employees	1,135	5,130	6,265	5,108
Other service charges	43,519	29,711	73,230	50,623
Incineration service charges	46,123	92,107	138,230	102,410
Incineration service recovery	-	(85,679)	(85,679)	(58,076)
Sale/disposal of fixed assets	-	903	903	948
Bank charges and overdraft interest	18,643	10,784	29,427	29,418
Total	113,996	53,794	167,790	153,329

26 Operating leases

icddr,b entered into various lease arrangements ranging from three months to five years. Rental payments for 2021 amounted to USD 321,413 (2020: USD 321,090). Future minimum lease payments are as follows:

Year	Amounts in USD		
	Restricted	Unrestricted	Total
Not later than one year	195,669	35,106	230,775
More than one year to five years	717,671	79,787	797,458
More than five years	8,923	-	8,923
Total	922,263	114,893	1,037,156

Please refer to note 3.07.



27 Breakdown of Total Expenditure

Functional expenses summary

	Amounts in USD	
	2021	2020
Research Programmes	58,689,376	43,626,507
Management and administration	10,627,058	12,046,663
Laboratory & Hospital	8,086,717	8,440,796
Total	77,403,151	64,113,966

In summary, 76% of the expenses was spent on research programmes, 14% was spent on management and administration and, 10% was spent on the laboratory and hospital. The percentages differ from the indirect cost rate report, as a result of applying the cost allowability principles in computing the indirect cost rate.

27.1 Detail of functional expenses

	Amounts in USD					
	2021	2021	2021	2021	2021	2020
	Direct Costs	Laboratory Costs	Central Management &	Hospital Costs	Total Costs	Total Costs
Salaries and benefits - local	29,840,075	2,071,611	6,046,094	2,861,134	40,818,914	36,877,177
Salaries and benefits - international	3,150,953	32,930	1,486,755	-	4,670,638	5,306,815
Salaries and benefits emeritus - international	1,123,251	-	14,897	-	1,138,148	1,066,100
Salaries and benefits emeritus - national	168,422	-	-	-	168,422	161,155
Consultancy fees	511,115	-	87,728	13,621	612,464	616,875
Travel and vehicle hire charges	2,458,021	54,243	492,553	73,738	3,078,555	2,221,314
Supplies and materials	7,814,047	1,988,488	537,064	570,820	10,910,419	7,362,999
Repairs and maintenance	394,256	36,938	77,980	24,436	533,610	383,625
Rent, communication and utilities	1,217,545	125,728	134,762	187,006	1,665,041	1,527,927
Printing and publications	355,405	6,250	103,358	1,292	466,305	389,902
Training, dissemination and staff development	1,137,043	2,206	12,162	2,488	1,153,899	790,834
Collaborative partnership costs	4,509,566	-	-	-	4,509,566	2,556,204
Hospital patient expenses	438,941	124	2,787	33,316	475,168	722,849
Cleaning and security charges	612,295	104,117	335,589	323,269	1,375,270	1,361,307
Legal and professional fees	482,905	55,273	254,461	532	793,171	397,815
Interdepartmental service charges	981,875	(771,267)	(269,105)	58,497	-	-
Doubtful debt expenses	-	-	208,776	-	208,776	-
Capital expenditure (restricted)	3,293,397	-	-	-	3,293,397	920,808
Depreciation	-	166,968	996,169	33,441	1,196,578	1,171,000
Other expenditures	113,996	8,157	24,276	21,361	167,790	153,329
Research support costs	19,302	-	(19,302)	-	-	-
Mandatory committee meeting expenses	66,966	-	100,054	-	167,020	125,931
Total	58,689,376	3,881,766	10,627,058	4,204,951	77,403,151	64,113,966

28 Financial risks

Financial instruments arising directly from icddr,b operations include accounts receivable, cash and cash equivalents, investments, contributions received in advance and accounts payable. icddr,b is exposed to various risks such as market risks, credit risks and liquidity risks. icddr,b seeks to minimize the potential adverse effects of these financial risks.

Credit risks

Credit risk is the risk that icddr,b may suffer a financial loss should Donors and, other market counterparties fail to fulfil their obligations. The carrying amount of financial assets represents the Centre's maximum credit exposures.

The organisation's maximum exposure to credit risk for the components of the statement of financial position is represented by the carrying amount as illustrated below:

	Amounts in USD	
	2021	2020
Donor receivables	16,156,942	13,356,596
Other receivables (time deposits)	97,439	53,473
Cash at bank	36,510,404	36,402,135
Balance as at 31st December	52,764,785	49,812,204

As at the date of preparing this report, icddr,b has not been notified by any donor of their inability to meet their obligations.

Market risks

Market risk is the risk that the value of icddr,b's investment will decrease due to movement in market factors such as changes in interest rates, foreign currency rates and equity prices. Foreign exchange risk arises from currency mismatches as well as timing differences between receipt of donor payments and payment of overseas obligations. Risk also arises where there is a significant fluctuation between the currency of the donor contracts signed and the currency of expenditure. icddr,b does not take any speculative positions in foreign exchange contracts nor in any derivative instruments.

As at 31st December 2021, icddr,b made a forex gain of USD 84,621, please refer to our Statement of Activities.

Interest rate risk

Interest rate risk is the risk that an investment's value will change due to a change in the absolute level of interest rates. icddr,b does not have interest-bearing borrowing and, is therefore not significantly exposed to interest rate risk.

icddr,b has time deposits of USD 11,672,517 which does not have any market value impact as they are mainly fixed deposits.

Liquidity risk

Liquidity risk is the risk that icddr,b may be unable to meet its obligations, when they fall due as a result of a sudden and potentially protracted increase in cash outflows. icddr,b seeks to maintain an adequate level of liquidity to meet its operational requirements and provide continuous funds for program activities.

icddr,b is maintaining a current ratio of 1.27 (\$57,440,178 / \$45,073,702).



29 Related parties

a) Key management personnel

The names and positions of key management personnel are as disclosed under the section Corporate Information.

b) Key management Compensation

	Amounts in USD	
	2021	2020
Salaries and allowances	2,536,087	3,383,221
Termination benefits	154,213	-
c) Balances due from employees	71,190	41,733

30 Contingent liability

A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity.

Assessing the amount of liabilities that are not probable is highly judgmental. Our best estimate of contingent liabilities as at 31st December 2021 is **BDT 48,937,099**, equivalent to **USD 585,302** arising from imposed tax by the DNCC and ex-staff labour tribunal.

As explained below there has been no material change in our total contingent liability in past periods;

Regarding the Writ Petition against DNCC, we filed the writ petition against DNCC as they imposed a holding tax of BDT 48,333,429 equivalent to USD 578,082 from the year 2013 to 2019. Our grounds included the fact that DNCC did not consider icddr,b as a non-profit charitable organization, whereas, the 1986 Rules has the provision for waiver of holding tax of non-profit charitable organizations. Besides, DNCC imposed the holding tax arbitrarily from the year 2013. Although the matter is totally upon the Honourable Court to decide, icddr,b believes that it has valid grounds based on which the Honourable Court issued the initial Rule Nisi.

Concerning the case filed by ex-staff of icddr,b at the Labour Tribunal, the claimant claimed for overtime of BDT 603,670 (2,278 hours X BDT 265 per hour rate) and gratuity of BDT 1,110,000 (BDT 30,000 X 37(28 years)); totalling BDT 1,713,670 equivalent to USD 20,496. Although the matter depends upon the Tribunal, icddr,b has valid grounds to defend the case. Firstly, the jurisdiction of the Court, considering icddr,b as a statutory organization filing a civil suit against icddr,b can be well challenged. Moreover, icddr,b paid all the overtime payments as per the applicable Staff Regulations and Rules (i.e. 15 hours per month); but this ground seems to be weak as there are no records of the claimant working more than 15 hours. The claim of the gratuity can be challenged on the ground that icddr,b is exempt from the Labour Act 2006 and under 1978 Ordinance icddr,b is required to follow its own rules/policy.

In each case above, we believe our position is strong, as a result, these have not been provided for and, are considered to be contingent liabilities.

31 Post COVID-19 Impact on icddr,b

Laboratory Income has recovered substantially in 2021 despite the ongoing pandemic. This was mainly due to substantial Covid-19 tests being conducted and the reopening of full laboratory services to the general public.

Restricted Grant Income – In 2021, our overall Restricted Grant Income increased by 32% compared to 2020, this is due to the reactivation of the ongoing projects, new large grants and additional project activities.

Donor relations - Our relationship with multiple donors has been extremely favourable throughout the pandemic period and to date. Overall, there is no material threat to the sustainability of icddr,b. In 2021 our surplus has increased significantly compared to 2020, thereby improving our operational reserves which can be used to sustain ourselves in future.

